These included 3-bromo-pyruvate (3-BrPA) [41, 42], which targets glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and HXK [43]; oxamate, which inhibits lactate dehydrogenase (LDH) [44, 45], and dichloroacetate (DCA), which acts instead by reversing the cancer-associated suppression of pyruvate dehydrogenase (PDH) through inhibition of pyruvate dehydrogenase kinase, thereby promoting the mitochondrial oxidation of pyruvate [46], and lonidamine [42, 47, 48], which inhibits HXK. Here, PDP1 is linked to cancer.